GSK plc (LON:GSK) Given Consensus Recommendation of “Hold” by Brokerages

Shares of GSK plc (LON:GSK) have been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is GBX 2,034.29.

GSK has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,900 price objective on shares of GSK in a report on Monday, June 8th. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Thursday, March 26th. Citigroup dropped their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research report on Thursday, May 28th.

GSK Price Performance

GSK stock opened at GBX 1,897 on Friday. The stock has a market capitalization of £75.99 billion, a P/E ratio of 13.35, a P/E/G ratio of 1.24 and a beta of 0.30. GSK has a 12-month low of GBX 1,288.61 and a 12-month high of GBX 2,282. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. The firm’s 50-day moving average is GBX 1,926.99 and its two-hundred day moving average is GBX 1,985.57.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. The firm had revenue of GBX 762.90 billion for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. Equities analysts predict that GSK will post 175.980975 earnings per share for the current year.

Insider Activity at GSK

In other news, insider Jeannie Lee bought 802 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average cost of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Vishal Sikka bought 1,266 shares of GSK stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, for a total transaction of £64,173.54. Insiders have purchased 7,625 shares of company stock worth $21,347,004 in the last 90 days. Company insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.